Common diabetes drug shows promise against kidney stone damage

Metformin, one of the world's most widely prescribed medications, may protect kidneys from injury caused by calcium oxalate crystals, according to new research. The finding could have implications for millions of patients with diabetes and kidney stone risk, potentially reducing expensive interventions and complications.

Originaltitel: Metformin suppresses calcium oxalate crystal-induced kidney injury by promoting Sirt1 and M2 macrophage-mediated anti-inflammatory activation